Corindus Partners With Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians

WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath^® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

Recently named the No. 1 hospital in Texas for the sixth year in a row by U.S. News & World Report, Houston Methodist Hospital brings together cardiologists, cardiovascular surgeons and cardiovascular anesthesiologists who take a collaborative approach to patient care and research. The hospital, which performs 1,100 PCIs annually, is adopting robotics to improve precision and enhance safety for cath lab professionals.

Mark Toland, President and Chief Executive Officer of Corindus, stated, “Houston Methodist is a world-class center and the ideal partner to educate the interventional community on current applications of robotics. The hospital’s leadership and innovation in cardiovascular medicine will help us to advance the field of vascular robotics.”

The Houston Methodist Institute for Technology, Innovation & Education (MITIE^SM), an innovative virtual hospital and hands-on clinical training facility, will be a robotic-assisted PCI training center. Physicians attending courses at Houston Methodist will participate in didactic education, live case observation with a trained robotic interventionalist, and a unique workshop for a hands-on introduction to robotic-assisted PCI.

Alan Lumsden, M.D., Chief of the Department of Cardiovascular Surgery at Houston Methodist, stated, “We pride ourselves on leading the way in embracing innovative technologies that improve patient care. With adoption of robotics in the cath lab on the rise, comprehensive training programs and innovative product developments are key factors for success.”

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath^® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

About Houston Methodist DeBakey Heart & Vascular Center

Patients from around the world choose Houston Methodist DeBakey Heart & Vascular Center for access to state-of-the-art resources at Houston Methodist Hospital in the Texas Medical Center. The center is staffed by more than 125 heart specialists and 1,000 employees, and boasts 10 operating rooms, 9 catheterization labs, 176 acute-care beds, 58 ICU beds and 43 transplant beds. The center has more than 100 clinical trials currently underway. The Center is ranked No. 21 by U.S. News & World Report among the 694 best hospitals in the United States for cardiology and heart surgery.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements that:

• Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted PCI; and
• leadership and innovation in cardiovascular medicine at Houston Methodist will help Corindus to advance the field of vascular robotics.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus’ website at http://www.corindus.com.